口腔人乳头瘤病毒（HPV）在健康人群和患有口腔鳞状细胞癌（OSCC）、口腔潜在恶性疾病（OPMD）和口腔良性病变（BL）等口腔疾病患者中的流行情况，在文献中并没有一致的描述。文献，数据稀缺且往往是异构的。此外，HPV 预防性疫苗在预防 HPV 相关口腔疾病方面的功效还很少被研究。我们对 10 年来收集的 1,415 份口腔冲洗样本中的 HPV 患病率和疫苗的潜在影响进行了分析，并根据以下因素分为四类：组织学/临床诊断。OSCC、OPMD 和 BL 患者以及可能接触 HPV (HPE) 的健康个体中的 HPV 患病率相当（12.7% vs. 27.2% vs. 13.5% vs. 9%）。疫苗影响的统计分析涉及计算高估计值和低估计值，并且仅显示低效应的显着差异。在 OSCC 和 HPE 患者中，非价疫苗的低估计值高于二价疫苗（29.6 vs. 51.9%，p < 0.05；18.2 vs. 42.4%，p < 0.05），而对于 OPMD 和 BL，二价低估计值的频率低于四价和九价（48.6 vs. 68.6%，p < 0.05；48.6 vs. 77.1%，p < 0.05；23.9 vs. 50.7%，p < 0.05；23.9 vs. 63.4%，p < 0.05）这项研究为了解口腔 HPV 的流行情况提供了新的见解，并表明在 OSCC 诊断存在的情况下，非有效疫苗可能比其他疫苗提供更好的保护。相反，四价疫苗可能足以预防 OPMD 和 BL。版权所有 © 2024 作者。由爱思唯尔公司出版。保留所有权利。

The prevalence of oral human papillomavirus (HPV) in the healthy population and patients with oral diseases such as oral squamous cell carcinoma (OSCC), oral potentially malignant disorders (OPMDs), and oral benign lesions (BL), is not consistently described in the literature, with scarce and often heterogeneous data. In addition, the efficacy of HPV prophylactic vaccines in preventing HPV-related oral disorders has been scarcely investigated.The prevalence of HPV and the potential impact of vaccines were analyzed in 1,415 oral rinse specimens, collected over 10 years and grouped into four categories based on histological/clinical diagnosis.HPV prevalence in OSCC, OPMD, and BL patients and in healthy individuals potentially exposed to HPV (HPE) was comparable (12.7 vs. 27.2% vs. 13.5 vs. 9%). Statistical analysis of the vaccine impact involved calculating high and low estimates and showed a significant difference only for the low effect. The nonavalent vaccine had higher low estimates than the bivalent vaccine in OSCC and HPE patients (29.6 vs. 51.9%, p < 0.05; 18.2 vs. 42.4%, p < 0.05), while for OPMD and BL, the frequency of bivalent low estimates was lower than that of quadrivalent and nonavalent (48.6 vs. 68.6%, p < 0.05 and 48.6 vs. 77.1%, p < 0.05; 23.9 vs. 50.7%, p < 0.05, and 23.9 vs. 63.4%, p < 0.05).This study provided new insights into the prevalence of oral HPV and showed that the nonavalent vaccine may provide better protection than the other vaccines in the presence of an OSCC diagnosis. Conversely, the quadrivalent vaccine may be sufficient to prevent OPMD and BL.Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.